ClinConnect ClinConnect Logo
Search / Trial NCT06612554

Zn Supplementation in HIV Immunological Non Responders

Launched by PARC DE SALUT MAR · Sep 22, 2024

Trial Information

Current as of June 23, 2025

Not yet recruiting

Keywords

Zinc Supplementation Hiv Immunological Non Responder Immune Response Immune Activation Inflammation

ClinConnect Summary

This clinical trial is studying whether taking zinc supplements can help improve the immune system in people living with HIV who have not been able to restore their CD4 T-cell counts despite receiving treatment. CD4 T-cells are important for fighting infections, and those who are considered Immunological Non-Responders (INRs) face a higher risk of infections and other health issues. The trial will involve participants who are at least 18 years old, have confirmed HIV, and have low zinc levels. They must also be on stable HIV treatment for a certain period and have low CD4 counts.

Participants in this study will be randomly assigned to either receive a daily dose of 75 mg of zinc along with their usual treatment or to continue their treatment without the zinc supplement. The researchers will monitor changes in CD4 counts, inflammation levels, and overall immune system function throughout the trial. This study aims to find out if zinc can be a simple and effective way to improve health for people in this situation, potentially leading to better quality of life. It’s important to note that zinc supplementation is generally safe, but it should be taken under medical supervision.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • confirmed HIV infection;
  • 18 years or older
  • Serum zinc levels less than 150ug/dl (normal range considered 75-150 ug/dl)
  • HIV-1 infection on stable ART for at least 3 months with cumulative ART duration of at least 6 months
  • Undetectable (less than 50copies/ml) persistently (isolated transient increases in viremia of less than 1000 copies/ml will be accepted)
  • Persistent less than 500CD4+ T-cells/mm3 at enrolment or an increase of less than 80 cells/mm3 after one year of viral undetectability
  • Exclusion Criteria:
  • Pregnancy
  • Lactation
  • Active infectious or inflammatory condition
  • Uncontrolled diabetes
  • Serum Zinc levels more than 150ug/dl

About Parc De Salut Mar

Parc de Salut Mar is a leading healthcare institution located in Barcelona, Spain, dedicated to advancing medical research and improving patient outcomes through innovative clinical trials. As a prominent sponsor, it focuses on a wide range of therapeutic areas, emphasizing collaboration between multidisciplinary teams of healthcare professionals and researchers. The institution is committed to adhering to the highest ethical standards and regulatory guidelines, ensuring the safety and well-being of participants while contributing to the development of cutting-edge treatments and therapies. With state-of-the-art facilities and a strong emphasis on patient-centered care, Parc de Salut Mar plays a vital role in the evolving landscape of clinical research.

Locations

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported